ORTEXORTEX News
Tracking BBD? Get live short interest, options flow, and signals on ORTEX.Sign up free →
BB
Earnings PreviewBBD

Bradesco Reports Today: Options Hedge Up, Insiders Bought the Dip

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 23 Oct 2026, 04:00

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

BBD reports Q3 results today with the put/call ratio at its highest level in over a month, even as insiders spent roughly $6.6 million buying shares in September.

Options positioning is the sharpest pre-earnings signal. The put/call ratio reached 1.18 on October 22, more than two standard deviations above its 20-day average of 0.91. That is the most defensive reading since mid-September, when the ratio briefly touched 1.24. The shift has been abrupt: through early October, the ratio was running below 0.85. Something changed investors' calculus in the second half of the month.

That shift has a plausible explanation in analyst action. HSBC downgraded BBD to Hold from Buy on October 8, setting a $3.90 target, essentially flat against the current $3.95 close. JP Morgan moved the other way on October 6, upgrading to Overweight from Neutral, without publishing a price target. The resulting consensus is genuinely split, two Holds and two Outperforms, which explains why options traders are paying for protection rather than leaning hard in either direction. The bear case centres on loan delinquency trends: a recent note flagged rising default rates in the consumer credit book, with delinquencies back to 2021 levels and net interest margin under pressure. The bull case rests on Bradesco's structural position as Brazil's second-largest private bank, with roughly 10% to 15% of domestic deposits and a dominant share in insurance, giving it earnings power that a single credit cycle cannot erase. The P/E of 7.6 and price-to-book of 1.1 leave room for rerating if the credit picture improves.

Insider buying cuts against the defensive positioning. Seven executives and directors purchased shares in mid-to-late September, with the net buy across 90 days totalling around 5.6 million shares and approximately $98 million in value. The transactions were executed at prices around 17.55 to 17.98 (in the local share equivalent), and none were filed under a pre-arranged 10b5-1 plan. That is a cluster of discretionary purchases immediately before a results date, not routine compensation-related activity. BlackRock also added meaningfully to its position, reporting 213 million additional shares held as of October 12, taking its stake to 6.7% of the company.

The lending market is notably calmer than it was heading into the October 15 peak, when borrow costs spiked to 4.88%. The rate has since fallen back to 2.43%, though that is still roughly five times the September average. Availability remains extremely loose at nearly 1,908%, meaning shares available to borrow dwarf those already lent. Short interest has crept up about 5% on the week to 22.5 million shares, but the ORTEX short score has fallen to 28.3 from 34.7 a week ago, indicating that short-side conviction has eased rather than built into the print. The two most recent quarterly results both produced negative reactions: BBD fell around 3% in a day and nearly 9.5% over five days after the August 2026 report.

Today's print will test whether the delinquency trend has stabilised enough to justify the recovery in the share price, which is up 12% over the past month despite a 2.5% slip on October 22.

Stocks in this article

See the live data behind this article on ORTEX.

Open BBD on ORTEX →

How this article was generated

Generated
23 Oct 2026, 04:02
Data as of
23 Oct 2026, 04:00
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.